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Abstract – Long-term PCV2 infection and/or concurrent infection with genotypes PCV2a and PCV2b may
play a role in the development of clinical porcine circovirus-associated disease (PCVAD). To evaluate this
premise, 24 11-week-old speciﬁc pathogen-free (SPF) pigs were randomly assigned to 1 of 4 treatments:
negative controls, a single inoculation with PCV2a, single inoculation followed by re-inoculation with a
homologous PCV2a strain, or repeated inoculations with heterologous strains (PCV2a, PCV2b). Pigs were
evaluated for clinical signs daily through 140 days post inoculation (dpi). Serum samples were collected
every other day from dpi 0 through 14 and weekly thereafter. PCV2-inoculated pigs were viremic by dpi 2
and 13 of 18 pigs remained viremic at 140 dpi. No statistical differences in the onset, level, or duration of
PCV2 viremia were detected among treatment groups. Anti-PCV2 antibodies were detected between 14 and
28 dpi and were present through 140 dpi without statistical differences in antibody response among
treatment groups. In the current study, pigs had extended viremia combined with detectable tissue PCV2
antigen levels despite the presence of high levels of anti-PCV2 antibody; however, no clinical disease was
observed.
PCV2 / heterologous challenge / persistence / viremia / serological response
1. INTRODUCTION
Porcine circovirus type 2 (PCV2) is a small,
single-stranded, circular DNAvirus [45] associ-
ated with respiratory, enteric, reproductive and
systemic disease [1]. To date, there are three
known genotypes of PCV2. PCV2a was
reported in archived porcine tissue samples
from northern Germany in 1962 [20] and anti-
PCV2 antibodies were detected as early as
1985 in the North America [27]. PCV2b was
reported in 2005 in North America and with
increasing frequency thereafter [7, 8, 18].
PCV2c was recently reported in Denmark
from archived serum samples from non-clinical* Corresponding author: tanjaopr@iastate.edu
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pigs in 1980, 1987 and 1990 [9]. PCV2c iso-
lates are more closely related to PCV2b
(95%) than PCV2a (91–93.6%) in sequence
homology [9].
The majority of experimental inoculation
studies have focused on characterizing the
infectivity and virulence of PCV2a isolates.
Experimental infection of colostrum-deprived
pigs demonstrated shedding of PCV2a DNA
in feces, nasal, oropharyngeal and tonsillar
secretions as early as one day post inoculation
(dpi) [2, 6, 43]. Viremia, nasal, oropharyngeal,
and fecal shedding of PCV2a DNA has been
reported to persist at least 70 days in colos-
trum-deprived pigs [43]. Characteristic lesions
(i.e. lymphocyte depletion and histiocytic
replacement within lymphoid tissues) appear
by 7 days post-infection and persist for variable
amounts of time [17]. Experimental infection of
conventional, speciﬁc-pathogen-free (SPF) pigs
has been shown to result in viremia by 2 dpi
and a detectable anti-PCV2 IgG response by
13 days post-infection [25]. Characteristic histo-
logical lesions were observed at 7 days post-
infection in SPF pigs [47]. Several case-control
studies have provided cross-sectional data
throughout the pig production cycle on viremia
and the serological response following natural
PCV2 infection in conventional swine herds.
These studies indicated that viremic animals
are commonly present in herds without clinical
signs at 11 weeks of age [24]. In herds with
clinical signs, viremic animals were present ear-
lier (7 weeks) [24] and, in most cases, the
amount of virus present was higher in clinically
affected pigs [5].
While the above-described studies focused
on viremia and seroconversion following
PCV2a infection, few have described experi-
mental PCV2b infection and even fewer have
attempted to assess the interactions between
strains of PCV2a and PCV2b. In one such
study, pigs were infected with PCV2a or
PCV2b and re-infected 35 days later with a het-
erologous strain [38]. All pigs were necropsied
56 days after the initial inoculation. Increased
levels of PCV2 DNA or anti-PCV2 antibody
were not observed in pigs dually infected with
PCV2a and PCV2b [38]. In a case-control
study [46], an association of porcine dermatitis
and nephropathy syndrome (PDNS) and high
levels of anti-PCV2 antibodies was described.
The authors observed that numbers of CD8+
cells were increased in renal tissues and hypoth-
esized that cytotoxic cells may be involved in
the pathogenesis of PDNS [46].
Most herds in North America are infected
with both PCV2a and PCV2b and the viruses
are likely endemic in most swine populations1.
Therefore, understanding the interactions
between PCV2a and PCV2b and their effect
on viremia, seroconversion, and the develop-
ment of clinical disease is important for devel-
oping diagnostic protocols and disease control
and prevention regimens. The objectives of this
study were to determine the long-term effect of
PCV2 infection, the effect of re-infection with a
homologous PCV2 strain, and the effect of
repeated infection with heterologous PCV2
strains on pathological, virological, serological,
and clinical parameters.
2. MATERIALS AND METHODS
2.1. Animals and housing
Twenty-four, 21-day-old, colostrum-fed, cross-
bred, castrated male pigs were purchased from a
herd known to be free of porcine reproductive and
respiratory syndrome virus (PRRSV) and swine
inﬂuenza virus (SIV) and seropositive for PCV2.
The pigs were weaned at 3 weeks of age and trans-
ported to the research facility at Iowa State Univer-
sity in Ames, Iowa, USA. On the day of arrival, the
pigs were randomly assigned to 1 of 4 groups. All
animals were housed in 2 m · 2.5 m pens in sepa-
rate rooms each equipped with one nipple drinker
and a self-feeder. All groups were fed a balanced,
pelleted, complete feed ration free of animal pro-
teins and antibiotics (Nature’s Made, Heartland
Coop, IA, USA) ad libitum. Two randomly selected
pigs (the pigs with the lowest identiﬁcation num-
bers) from each group were tested and found to
be negative for antibodies to porcine parvovirus
(PPV), PRRSV, H1N1 SIV, H3N2 SIV, and Myco-
plasma hyopneumoniae on arrival at the research
facility at 3 weeks of age and at necropsy at 31
weeks of age.
1 Opriessnig T., personal observation.
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2.2. Experimental design
The experimental protocol was approved by the
Iowa State University Institutional Animal Care and
Use Committee (IACUC number 3-06-6083-S).
The experimental design is summarized in Table I.
Each pig in 3 of the 4 groups received PCV2 strain
40895 at 11 weeks of age (dpi 0). Six pigs (R-
PCV2a) were re-challenged with PCV2a strain
40895 at 35, 70, and 105 dpi. Each pig in the R-
PCV2a/b group alternatively received PCV2a (dpi 0
and 70) and PCV2b (dpi 35 and 105). The two
PCV2a strains used were heterologous. Blood sam-
ples were collected on arrival, dpi 0, 2, 4, 6, 8, 10,
12, 14, and weekly thereafter until necropsy on
dpi 140. All pigs were necropsied 140 dpi at 31
weeks of age. The presence, level, and duration of
PCV2 viral DNA and anti-PCV2-antibodies in serum
samples were compared across groups. Presence and
level of neutralizing PCV2-antibodies in all pigs were
compared at 10, 14, 21, 42, 105, 112, and 140 dpi. In
addition, the average scores of the overall PCV2-
associated lymphoid lesions and incidence of PCV2
antigen were compared at 140 dpi.
2.3. PCV2 isolates and inoculation
The virus inocula were produced by transfecting
PK-15 cells with infectious PCV2 stock as previously
described [34]. PCV2 strain 40895 (PCV2a) (Gen-
Bank accession number AF264042) was recovered
from an Iowa farm in 1998 [11] and has been well
characterized genetically [11] and in the SPF pig
model [12–14, 32–35, 37–39]. PCV2a 40895 was
administered at a dose of 104.5 50% tissue culture
infectious dose (TCID50) intramuscularly (1 mL)
and intranasally (2 mL). Using two inoculation routes
was done to ensure that all pigs became infected at
the same time as previously described [25, 35].
PCV2b strain ADDLPP 10069 (GenBank acces-
sion number EU594437) was isolated from lung tissue
homogenate obtained from a pig in Indiana suffering
clinical PCVADon a farmexperiencing approximately
25% mortality. PCV2b strain ADDLPP 10069 was
administered at a doseof 104.5 TCID50 intramuscularly
(1 mL) and intranasally (2 mL).
PCV2a isolate 4838 (GenBank accession number
DQ397521) was recovered from a subclinically-
infected pig on an Iowa farm in 2003 [34]. PCV2a
strain 4838 was given at a dose of 0.5 · 103.5
TCID50 intramuscularly (2 mL) and intranasally
(2 mL). The lower dose of the PCV2a 4838 inocu-
lum was due to difﬁculty in growing the virus to a
high titer in vitro.
2.4. Clinical evaluation
Following PCV2-inoculation, the pigs were eval-
uated daily for clinical signs including but not limited
to wasting, lethargy, and anorexia.
2.5. Diagnostic assays
2.5.1. Anti-PCV2-IgM-antibodies
Serum samples were tested by a commercially
available PCV2 ELISA IgM assay (Ingenasa,
Madrid, Spain) with results expressed as optical den-
sity (O.D.) at 450 nm. At this wavelength, the posi-
tive had to produce an O.D. of at least 0.7
Individual plate cutoffs were determined by multiply-
ing the average O.D. value of the positive control
well by 0.4 as recommended by the manufacturer.
Table I. Experimental design.
Group designation Inoculation (weeks of age) Necropsy
11 16 21 26 31
0 dpia 35 dpi 70 dpi 105 dpi 140 dpi
Negative controls (n = 6) – – – – 6 pigs
PCV2a (n = 6) PCV2ab – – – 6 pigs
R-PCV2a (n = 6) PCV2ab PCV2ab PCV2ab PCV2ab 6 pigs
R-PCV2a/b (n = 6) PCV2ab PCV2bd PCV2ac PCV2bd 6 pigs
a Days post inoculation (dpi).
b Strain 40895.
c Strain 4838.
d Strain ADDLPP 10069.
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2.5.2. Anti-PCV2-IgG-antibodies
An in-house ORF2-PCV2 IgG ELISA was pre-
pared and used as previously described [31]. Samples
were considered positive if the calculated sample-to-
positive (S/P) ratio was 0.2 or greater. Previously, this
ELISA has shown to have a sensitivity and speciﬁcity
of 100% at the S/P ratio 0.2 cutoff using samples
from experimentally infected pigs on trial day 49
[41].
2.5.3. PCV2 neutralizing antibodies
A ﬂuorescence focus neutralization assay was
done on serum samples collected on 10, 14, 21, 42,
105, 112, and 140 dpi to determine the presence of
neutralizing antibodies against PCV2 according to
the Iowa State University Veterinary Diagnostic Lab-
oratory standard operating protocol [42]. The assay
was performed with PCV2a isolate ISU-98-15237.
2.5.4. Additional serology
The serum samples from 2 randomly selected pigs
in each group taken on arrival at the research facility
and at necropsy were tested for the presence of anti-
bodies to PRRSV by PRRSV-ELISA (IDEXX Labo-
ratories, Inc. Westbrook, MA, USA), PPV by
hemagglutination inhibition (HI) assay [30], M. hyo-
pneumoniae by ELISA [3], and H1N1 SIV and
H3N2 SIV by HI assays according to the protocols
used at the Veterinary Diagnostic Laboratory at Iowa
State University.
2.5.5. PCV2 DNA quantiﬁcation
DNA-extraction was done on 200 lL of the
serum samples collected on dpi 0, 2, 4, 6, 8, 14
and weekly thereafter until 140 dpi was performed
using the QIAamp DNA Mini Kit (Qiagen, Valen-
cia, CA, USA). DNA-extracts were used for quantiﬁ-
cation of PCV2 genomic DNA copy numbers by
real-time PCR [32]. A sample with no threshold cycle
(CT) reading during the 40 ampliﬁcation cycles was
considered to be negative.
2.6. Differentiation of PCV2a and PCV2b DNA
by a quantitative multiplex real-time PCR
Serum samples obtained from all pigs in the R-
PCV2a and R-PCV2a/b groups at dpi 35, 70, 105,
and 140 were tested for PCV2a and PCV2b DNA
by a multiplex quantitative real-time PCR. In brief,
a forward (50-GCAGGGCCAGAATTCAACC-30)
and a reverse primer (50-GGCGGTGGACATGATG
AGA-30), a probe speciﬁc for PCV2a (50-Cal Fluor
Orange 560-GGGGACCAACAAAATCTCTATAC
CCTTT-BHQ-30), and probe speciﬁc for PCV2b
(50-Quasar 670-CTCAAACCCCCGCTCTGTGCC
C-BHQ-30) were designed in the Capsid-coding
region of PCV2. The multiplex real-time PCR reac-
tion consisted of a total volume of 25 lL containing
12.5 lL of the commercially available master mix
(TaqMan Universal PCR master mix, PE Applied
Biosystems), 5 lL DNA, 0.4 lM of each primer,
and 0.2 lM of each of the probes. The reactions were
carried out in a 7500 Fast Real-Time PCR system
(ABI, Foster City, CA, USA) under the following
conditions: 50 C for 2 min, 95 C for 10 min, fol-
lowed by 40 cycles of 95 C for 15 s and 60 C
for 1 min. The sensitivity and speciﬁcity of the
real-time PCR reaction was evaluated by using
known PCV2a and PCV2b isolates as well as PPV,
PRRSV, and PCV type 1 (PCV1) isolates.
2.7. Necropsy
Necropsies were performed on all pigs at 140 dpi.
The total amount of macroscopic lung lesions rang-
ing from 0 to 100% of the lung affected and the size
of lymph nodes ranging from 0 (normal) to 3 (four
times the normal size) were estimated in a blinded
fashion [38]. Lungs were insufﬂated with ﬁxative.
Sections of lymph nodes (superﬁcial inguinal, medi-
astinal, tracheobronchial, mesenteric), tonsil, thymus,
ileum, kidney, colon, spleen, and liver were collected
at necropsy and ﬁxed in 10% neutral-buffered forma-
lin and routinely processed for histological
examination.
2.8. Histopathology
Microscopic lesions were evaluated in a blinded
fashion by two veterinary pathologists (TO, PGH).
Lung sections were scored for the presence and
severity of interstitial pneumonia using the following
scores: 0 (normal), 1 (mild focal), 2 (mild diffuse),
3 (moderate focal), 4 (moderate diffuse), 5 (severe
focal) and 6 (severe diffuse). Sections of heart, liver,
kidney, brain, ileum, and colon were evaluated for the
presence of lymphohistiocytic inﬂammation and
scored from 0 (none) to 3 (severe). Lymphoid tissues
including lymph nodes, tonsil, and spleen were eval-
uated for the presence of lymphoid depletion ranging
from 0 (normal) to 3 (severe) and histiocytic inﬂam-
mation and replacement of follicles ranging from
0 (normal) to 3 (severe) [33].
Vet. Res. (2010) 41:31 T. Opriessnig et al.
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2.9. Immunohistochemistry (IHC)
IHC for detection of PCV2-speciﬁc antigen was
performed on selected formalin-ﬁxed and parafﬁn-
embedded sections of lymph nodes (superﬁcial ingui-
nal, mediastinal, tracheobronchial, and mesenteric),
tonsil, spleen, Peyer’s patches, and thymus using a
rabbit polyclonal antiserum [44]. PCV2-antigen scor-
ing was done in a blinded fashion and scores ranged
from 0 (no signal) to 3 (more than 50% of the lym-
phoid follicles contain cells with PCV2-antigen stain-
ing) [33].
2.10. Sequencing
PCR products ampliﬁed from virus recovered
from one randomly selected pig at 140 dpi from each
inoculation group were sequenced and compared to
the respective original inoculum. Nested PCR was
used to amplify the entire ORF2 gene for sequencing
and subsequent sequence comparison [34]. The PCR
products were run on a 1% agarose gel and the
expected 820 bp products were excised, puriﬁed
and sequenced at the Iowa State University Sequenc-
ing facility. The sequences were analyzed and com-
pared to the sequences of the original virus inocula.
2.11. Statistical analysis
Summary statistics were calculated for all groups
to assess the overall quality of the data, including nor-
mality. Continuous repeated measured data (antibody
levels, viremia) were assessed with the multivariate
analysis of variance method (MANOVA). If the group
by time interaction was signiﬁcant (p < 0.05) the
cross-sectional analysis was used to determine the
signiﬁcant time points [21]. Analysis of variance
(ANOVA) was used for cross-sectional assessment
of continuousmeasures. The rejection level for the null
hypothesis was 0.05 followed by pairwise testing
using the Tukey–Kramer adjustment. The severity
of non-repeatedmeasures of necropsy and histopathol-
ogy datawere assessed using non-parametricKruskal–
Wallis one-way ANOVA. If this was signiﬁcant
(p < 0.05), then pairwise Wilcoxon test was used to
assess differences between groups.Differences in inci-
dence of macroscopic and microscopic lesions were
evaluated by using Fisher’s exact test. The Pearson
product-moment correlation coefﬁcient was used
to determine the relation between neutralizing
anti-PCV2 antibody levels and PCV2 DNA levels.
Statistical analysis was performed using JMP software
(JMP version 6.0.0, SAS Institute Inc., Cary, NC,
USA).
3. RESULTS
3.1. Clinical disease
Clinical disease was not observed in any of
the pigs. All pigs remained clinically healthy
until termination of the study.
3.2. Anti-PCV2 antibody responses over time
The mean anti-PCV2 IgM responses in each
group are summarized in Figure 1. The preva-
lence of anti-PCV2 IgM antibodies was as fol-
lows: 4/6 PCV2 pigs, 2/6 R-PCV2a pigs and 2/
6 R-PCV2a/b pig were positive at 12 dpi, 5/6
PCV2, R-PCV2a R-PCV2a/b pig were positive
at 14 dpi, 3/6 PCV2 pigs, 6/6 R-PCV2a pigs
and 2/6 R-PCV2a/b pig were positive at 21 dpi,
and 2/6 R-PCV2a/b pigs were positive at 28 dpi.
There was a signiﬁcant (p < 0.05) time by group
interaction when the mean group O.D. values
were analyzed; however, this was not the case
when only the PCV2 inoculated groups were
analyzed. The mean O.D. levels were signiﬁ-
cantly increased at 10 dpi (p = 0.03; R-PCV2a/
b pigs versus controls), 12 dpi (p = 0.03;
R-PCV2a/b and PCV2a pigs versus controls),
14 dpi, 21 dpi, 28 dpi, 35 dpi (all: p < 0.01;
PCV2 inoculated groups versus controls), 42 dpi
(p = 0.01; R-PCV2a and R-PCV2a/b pigs ver-
sus controls), 48 dpi and 56 dpi (both:
p = 0.03; R-PCV2a pigs versus controls). In
the later stages of the study, the infection with
homologous or heterologous PCV2 isolates did
not affect the serum anti-PCV2 IgMO.D. levels.
The mean anti-PCV2 IgG responses in each
group are summarized in Figure 2. There was a
signiﬁcant (p < 0.05) time by group interaction
when all groups were analyzed; however, this
was not the case when only PCV2 inoculated
groups were analyzed. Five of eighteen, 8 of
18, 17 of 18, and 18 of 18 PCV2-inoculated
pigs had positive anti-PCV2-IgG S/P ratios by
12, 14, 21, and 28 dpi, respectively. By 14 dpi,
mean group S/P ratios were signiﬁcantly
(p = 0.018) different between control pigs and
the R-PCV2a/b group. By 21 dpi, the group
means of all inoculated groups were above
the 0.2 ELISA cut-off (Fig. 2). All inoculated
pigs remained seropositive until termination of
Long-term PCV2 infection Vet. Res. (2010) 41:31
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the study at 140 dpi and had signiﬁcantly
(p < 0.001) higher mean group S/P ratios com-
pared to the control group. All negative control
pigs remained negative throughout the study.
From 21 dpi onwards, there were no statisti-
cally signiﬁcant differences between PCV2-
inoculated groups regardless of re-infection
with homologous or heterologous strains except
for dpi 140 where PCV2a pigs had signiﬁcantly
(p < 0.01) higher mean S/P ratios compared to
the R-PCV2a/b group.
Log-transformed group mean anti-PCV2
neutralizing antibody levels are summarized in
Figure 3. By 21 dpi, neutralizing antibodies
were detectable and the mean group values
were different from the negative control levels
and remained signiﬁcantly (p < 0.05) higher
for the remainder of the study. There were no
signiﬁcant differences in neutralizing antibody
levels among the PCV2-inoculated groups
regardless of the infection status.
3.3. PCV2 DNA loads in serum samples over
time
The group mean serum PCV2 DNA loads
over time are summarized in Figure 4. There
was a signiﬁcant (p < 0.05) group by time
interaction. Eight of 18 pigs inoculated
with PCV2a were viremic by 2 dpi (Tab. II).
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Figure 1. Mean group anti-PCV2 IgM response over time (± SE). Arrows indicate the timing of PCV2
inoculation in groups PCV2a, R-PCV2a and R-PCV2a/b and reinoculation in groups R-PCV2a and
R-PCV2a/b. The line indicates the average plate cutoff values. Individual plate cutoff values were
determined by multiplying the average O.D. value of the positive control well by 0.4 as recommended by
the manufacturer.
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Figure 2. Mean group anti-PCV2 IgG response over time (measured by an ORF2-based ELISA assay)
(± SE). Arrows indicate the timing of PCV2 inoculation in groups PCV2a, R-PCV2a and R-PCV2a/b and
reinoculation in groups R-PCV2a and R-PCV2a/b.
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By 14 dpi, all 18 PCV2-inoculated pigs were
PCV2 viremic. The amount of PCV2 DNA in
serum in PCV2 inoculated groups was signiﬁ-
cantly different (p < 0.001) compared to con-
trol pigs starting on dpi 6 through dpi 77 and
again on dpi 133 and 140. Individual pigs in
all three PCV2 inoculated groups became neg-
ative for PCV2 DNA for up to seven consecu-
tive bleeding days (Tab. II) but the majority of
the pigs in all three groups remained viremic
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Figure 3. Log10 transformed mean group neutralizing antibody response (± SE). PCV2 inoculations were
done on 0 dpi in the PCV2, R-PCV2a, and R-PCV2a/b groups and PCV2 reinoculations were done on 35,
70, and 105 dpi in the R-PCV2a and R-PCV2a/b groups.
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Figure 4. Mean group log10 PCV2 DNA levels over time (± SE). Arrows indicate the timing of PCV2
inoculation in groups PCV2a, R-PCV2a and R-PCV2a/b and reinoculation in groups R-PCV2a and
R-PCV2a/b. A sample with no threshold cycle (CT) reading during the 40 ampliﬁcation cycles was
considered to be negative.
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until the termination of the study at 140 dpi at
which time the PCV2 DNA was detected in
13/18 pigs in sera. There were no statistical
differences (p > 0.05) in the level of PCV2
viremia in the three PCV2 inoculated groups;
however, the mean group DNA amount in
serum was also not different (p > 0.05) from
the control pigs starting by dpi 84 until dpi
126. There was no increase in the amount of
PCV2 DNA in sera after re-infection with
homologous PCV2 (in the R-PCV2a group)
or after challenge with a heterologous PCV2
strains (in the R-PCV2a/b group) compared to
pigs singularly infected with PCV2a (Fig. 4).
Log-transformed PCV DNA levels and log-
transformed neutralizing antibody levels had a
correlation coefﬁcient of 0.1368 on dpi 21
and 0.4012 on dpi 140.
3.4. PCV2 genotype present in the pigs
PCV2b DNA was not detected in pigs from
the R-PCV2a group on 35, 70, 105, and
140 dpi. In the R-PCV2a/b group, low levels
of PCV2b DNA were detected in two pigs on
dpi 140 (1.3 · 104 and 7.5 · 103 genomic cop-
ies/mL serum, respectively) but not on any of
the other days tested. Sequencing of the PCV2
ORF2 from one randomly selected pig in each
of the PCV2-inoculated groups on dpi 140 con-
ﬁrmed the presence of PCV2a (100% nucleotide
sequence identity with PCV2 strain 40895).
Table II. Presence (+) or absence () of PCV2 DNA as determined by real-time PCR on serum collected at
different days post PCV2a inoculation. Reinoculation in groups R-PCV2a and R-PCV2a/b occurred on days
35, 70, and 105.
Pig ID 0 2 4 6 8 14 21 28 35 42 49 56 63 70 77 84 91 98 105 112 119 126 133 140
Controls
1214                        
1237                        
1249                        
1261                        
1279                        
1296                        
PCV2a
1211    + + + + + + + + + + + +  +  + + + +  
1213  + + + + + + + + + + + + + + + + + + + + + + +
1290   + + + + + + + + + + + + + + + + + + + + + +
1291    + + + + + + + +   +   + +     + +
1295    + + + + + + + + + + +       + +  
1298  + + + + + + + + + + +        +    +
R-PCV2a
1241  + + + + + + + + + + + + + + + + + + + + + + +
1265     + + + + + + + + + + + + + + + +   + +
1266    + + + + + + + + + + + + + + +  + + + + +
1277  + + + + + + + + + + +     +      + +
1287  +  + + + + + + + + + + + +    +     
1294   + + + + + + + + + + + + + + + + + + + + + +
R-PCV2a/b
1212    + + +   + + +       +    +  +
1263  +  + + + + + + + + + + + + + + + +  +  + +
1272      + + + + + + + + + +     +    
1275  + + + + + + + + + + + + + + + +       
1293   + + + + + + + + + + + + +       + + +
1297  + + + + + + + + + + + + + + + + + + + + + + +
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3.5. Macroscopic and microscopic lesions and
the amount of PCV2 antigen in tissue
samples collected at 140 dpi
Macroscopic lesions were not observed in
any of the pigs. Microscopically, 2/6 pigs
in the PCV2a inoculated group and 1/6 pig in
the R-PCV2a group had mild lymphoid deple-
tion, 1/6 pigs (PCV2a) had moderate histiocytic
replacement of follicles in lymphoid tissues, 1/6
controls, 4/6 PCV2a, 4/6 R-PCV2a and 1/6 R-
PCV2a/b pigs had mild focal lymphohistiocytic
hepatitis, and 3/6 R-PCV2a, 1/6 PCV2a and R-
PCV2a/b pigs had mild-to-moderate lymphoh-
istiocytic interstitial nephritis. Mild interstitial
pneumonia (score 1) was observed in 2/6
PCV2a pigs, 3/6 R-PCV2a pigs, and 3/6 R-
PCV2a/b pigs. The incidence or severity of
the lesions was not signiﬁcantly (p > 0.05) dif-
ferent between groups.
Low amounts of PCV2 antigen was found
in lymphoid tissues in 2/6 PCV2a pigs
(Fig. 5), 1/6 R-PCV2a pigs, and 2/6 R-
PCV2a/b pigs by using a PCV2-speciﬁc IHC
method. There were no statistical differences
(p > 0.05) in incidence of PCV2 antigen in
tissues between groups.
4. DISCUSSION
Among 97 diagnostic submissions from ﬁeld
cases collected in the USA, PCV2a/b co-infec-
tion was demonstrated by PCR in 25% of the
clinical samples [18]. We observed that PCV2
infection resulted in an anti-PCV2 IgM response
Figure 5. Lymph node, pig, inoculated with porcine circovirus type 2 (PCV2) 140 days previously.
Immunohistochemical staining using a polyclonal antiserum against PCV2 revealing scant brown staining
in the cytoplasm of macrophages-like cells in the center of lymphoid follicles. Streptavidin-biotin-
peroxidase complex method counterstained with hematoxylin. Bar = 40 lm. (A color version of this ﬁgure
is available at www.vetres.org.)
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followed by a strong anti-PCV2 IgG response in
serum and a high prevalence of long-term PCV2
viremia. Individual PCV2 DNA-negative pigs
were found throughout the study and some of
those pigs (2/18) remained PCV2DNA negative
for up to 7 consecutive bleedings; however, at
termination of the study, 13 of 18 PCV2 inocu-
lated pigs were viremic. The observed intermit-
tent PCV2 viremia pattern may be due to
differences in replication kinetics, differences
in replication sites, stressors, host susceptibility,
or re-inoculation. Alternatively, it may be due
to the detection limit of the PCR used. Samples
were considered positive when the CT value
was less than 40. Samples were considered
negative when there was no observed CT value
during the 40 ampliﬁcation cycles. However,
false positive results may arise due to overlap
with background noise and accurate discrimina-
tion between positive and negative animals at
high CT values may not always be possible.
Persistent chronic infection is deﬁned as
establishment of equilibrium between the virus
and the host’s immune system, resulting in an
infection of long duration. The present study
demonstrated persistence of PCV2 through the
140 day observation period in conventional
pigs. Previously, Bolin et al. [4] described
detection of viremia for 125 dpi in cesarean-
derived, colostrum-deprived pigs inoculated at
3 weeks of age. PCV2 was also successfully
isolated from several tissues obtained from the
pigs on 125 dpi. The authors concluded that
the extended duration, after experimental inocu-
lation with PCV2, and isolation of infectious
virus from multiple tissues indicated the estab-
lishment of a persistent infection [4]. Likewise,
in a study investigating persistence in sows with
subsequent vertical transmission to piglets,
PCV2 antigen was detected in lymphoid tis-
sues, lungs, myocardium, and epithelial cells
of the pinna of piglets born to sows inseminated
with PCV2-spiked semen [26].
The predominate genotype of PCV2 identi-
ﬁed in the group with repeated heterologous
PCV2 challenges (R-PCV2a/b) was the PCV2a
used for the initial infection. PCV2b was only
detected in two pigs on the day of necropsy.
This is similar to what has been previously
described [38] and further conﬁrms that PCV2
isolates are cross-protective and prior infection
with PCV2a prevents or limits re-infection with
a heterologous PCV2b strain. However, timing
of concurrent or re-infection likely varies
greatly in the ﬁeld and may inﬂuence the devel-
opment of viremia. In this study, re-infection
occurred 5 weeks after the initial infection.
Although the anti-PCV2 antibodies present
in the pigs were shown to have neutralizing
capabilities, this was not correlated with a
reduction of PCV2 viremia (correlation coefﬁ-
cient of 0.1368 on dpi 21 and 0.4012 on
dpi 140). This is in contrast to what has been
reported previously where neutralizing antibod-
ies were found to be correlated with protection
against replication and development of disease
[28, 29]. Gnotobiotic or SPF pigs with high lev-
els of neutralizing antibodies did not have
detectable PCV2 replication in inguinal lymph
nodes. However, the differences in the pig
source (gnotobiotics or SPF pigs versus con-
ventional pigs), age of the pigs at inoculation
(3 weeks of age versus 11 weeks of age), sam-
pling protocols (lymph nodes biopsies versus
serum), differences in the assays used to mea-
sure neutralizing antibodies, and study out-
comes (clinically affected pigs versus healthy
pigs) between the studies were considerable
and directly comparing the results is problem-
atic. In addition, while in the previous studies
the pigs were monitored until dpi 21 [28, 29]
when neutralizing anti-PCV2 antibodies just
start to appear in serum, in the current experi-
ment the pigs were monitored for 140 days post
initial infection. Also, virus isolation titration on
lymph nodes was used to determine presence of
replicating PCV2 [28, 29]. In the current study,
we determined the amount of PCV2 DNA in
serum by quantitative real-time PCR. The
PCR assay used [32] does not discriminate
between viable and/or replicating PCV2 and
non-viable PCV2 or DNA remnants. In addi-
tion, it needs to be considered that some of ani-
mals that were PCR positive had values close to
the PCR cutoff and the biological signiﬁcance
of a low viremia level and the correlation with
neutralizing antibody levels is unknown. How-
ever, PCV2 antigen was demonstrated by IHC
in lymphoid tissues collected from pigs infected
140 days previously (Fig. 5). Others have
Vet. Res. (2010) 41:31 T. Opriessnig et al.
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estimated that a minimum viral load of 108
PCV2 genomes per 500 ng DNA is required
in order to give visible IHC staining [5]. A high
tissue level of PCV2 140 dpi despite the pres-
ence of high levels of anti-PCV2 IgG suggests
that replicating PCV2 was still present locally.
In addition, more recently Fort et al. [15]
reported on co-existence of neutralizing anti-
bodies and viral DNA in serum samples
obtained from both clinically affected and
non-affected pigs which reinforces that neutral-
izing antibodies alone are not sufﬁcient for
PCV2 clearance.
The results of the current study suggest that
PCV2a and PCV2b co-infection administered
35 days apart is not sufﬁcient to induce clini-
cal disease in a conventional pig model. How-
ever, experimental infection of conventional
SPF pigs with PCV2 results in persistent viral
infection despite the presence of high levels of
anti-PCV2-antibodies. A similar pattern was
not only seen in re-infected animals but also
in the PCV2a group which was inoculated
only once 140 days prior to termination of
the study.
All current commercially available PCV2
vaccines are killed products [36] and have been
shown to reduce the level and length of PCV2
viremia in experimental models [16, 37, 39, 40]
and under ﬁeld conditions [10, 19, 23]. Reduc-
tion or elimination of PCV2 viremia after
challenge was not observed in this study. Rea-
sons for this may be that the initial viral infec-
tion results in persistence of the virus in cells of
the immune system which may potentially
interfere with antigen recognition or recall
responses [22]. Killed vaccine products, on
the other hand, apparently are sufﬁcient to
induce a protective sterilizing immune response
against infections with live PCV2 when the
vaccine is given prior to virus challenge. The
efﬁcacy of PCV2 vaccines in PCV2 persistently
infected pigs is currently unknown and needs to
be further investigated.
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